< Back to latest news & events

Event

IAM Pharma & Biotech IP Summit 2020 – London

January 2020

Event date: 28th January 2020

HGF is a gold sponsor at IAM Pharma & Biotech IP Summit on 28th January 2020 with Partner Douglas Drysdale and Patent Director Dr Emma Longland attending the event.

The life sciences are in a period of dramatic change and innovation with developments in new technologies challenging traditional IP strategies and business models. IAM’s Pharma and Biotech IP will bring together leading in-house practitioners and expert counsel to discuss next-generation strategies for protecting and exploiting cutting-edge innovation.

HGF Partner Douglas Drysdale will be attending and joining a panel to discuss Protecting the next generation of therapies:

A wave of cutting-edge technologies – from personalised medicines to gene and cell therapies – have become the focus of innovation in the life sciences, raising new challenges for IP professionals. An expert panel will shed light on:

  • The patentability questions raised by new technologies
  • How to gain the strongest possible protection for these technologies
  • Relevant international differences

HGF Patent Director Dr Emma Longland will also be attending.

Register here

Attendees

Douglas
Drysdale

Latest updates

Exam Success!

HGF are delighted to announce success for many of our colleagues in the recent exams on becoming qualified attorneys and would like to congratulate them on this fantastic achievement. Martyn …

Read article

In2ScienceUK continues to promote diversity and inclusion in STEM and IP with its award winning programme

HGF are proud sponsors of In2ScienceUK, a charity that gives young people from low-income backgrounds the opportunity to gain essential insights into science, technology, engineering, and mathematics (STEM) careers with …

Read article

Spotting innovation in digital health – and can you patent it?

Intellectual Property (IP) can add significant value to your business, providing a competitive edge over the market, as well as demonstrating sound business planning to help secure investment. There are …

Read article

Innovation at the heart of UK medtech strategy

The UK Department of Health and Social Care has recently published the government’s first ever medical technology strategy in an effort to accelerate access to innovative technologies. The strategy document …

Read article

How medtech start-ups can supercharge their IP for fundraising

Why is IP important for fundraising? Intellectual property (IP) rights underpin the value of most medtech start-up companies. IP rights include patents, design rights, trade marks, copyright and trade secrets …

Read article

What is EUDAMED and how will it affect your IP strategy?

The “European database on medical devices”, or “EUDAMED”, is the EU’s IT system created by the new Medical Devices Regulation (MDR) and In Vitro Diagnostics Medical Devices Regulation (IVDR). When …

Read article
See all updates